Purpose. To determine the efficacy, safety, and predictive outcome factors for intravitreal dexamethasone implant (DEX) in\npseudophakic cystoid macular edema (PCME). Methods. Retrospective, interventional, controlled study. Patients included\nhad to have clinically significant PCME and have been treated with the DEX between 2012 and 2015. Charts and oneyear\ndata were selected consecutively, and efficacy and safety were abstracted. Visual acuity (VA) and central foveal\nthickness (CFT) were analysed. Results. Nineteen patient data sets were analysed. After treatment with DEX, mean VA\nincreased significantly by 0.2 logMAR (p = 0 034), while the mean CFT was reduced significantly by 162.79 �¼m (p < 0 001).\nFive patients receiving a combination of DEX/bevacizumab have not experienced a higher mean VA gain or CFT\nreduction compared to fourteen patients receiving DEX alone. Decision rules, when to combine DEX with bevacizumab,\nhave not been defined before the study. Only posttreatment VA gains in the nonhypertensive subgroup (n = 11) were\nsignificantly better (p = 0 026). Analysis of data from diabetes patients (n = 4) versus nondiabetics yielded no significant\ndifferences in efficacy. There have been no adverse events within follow-up time. Conclusion. The use of DEX in\nPCME showed significant improvements in VA and CFT. The VA seems to show greater improvements in patients\nwithout hypertension.
Loading....